Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 07:00 ET | Source: MediciNova, Inc.

MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...
October 30, 2025 19:00 ET | Source: MediciNova, Inc.

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

LA JOLLA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...
October 06, 2025 08:00 ET | Source: MediciNova, Inc.

MediciNova to Present at the LD Micro Main Event XIX Investor Conference

LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock...
September 22, 2025 08:00 ET | Source: MediciNova, Inc.

MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)

LA JOLLA, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...
September 16, 2025 08:00 ET | Source: MediciNova, Inc.

MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND

LA JOLLA, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...
September 08, 2025 09:00 ET | Source: MediciNova, Inc.

MediciNova Provides Shareholder Update on Key Developments

LA JOLLA, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock...
September 03, 2025 07:00 ET | Source: MediciNova, Inc.

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

LA JOLLA, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...
August 26, 2025 19:00 ET | Source: MediciNova, Inc.

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

LA JOLLA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock...
July 31, 2025 19:30 ET | Source: MediciNova, Inc.

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

LA JOLLA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock...
July 24, 2025 06:00 ET | Source: MediciNova, Inc.

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

LA JOLLA, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...